Global Chronic Spontaneous Urticaria Market Major Players 2024, Forecast To 2033
22 Aug, 2024
The chronic spontaneous urticaria market has seen strong growth, with its size increasing from $1.90 billion in 2023 to $2.06 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. This growth is attributed to improved diagnostic tools, increased awareness among healthcare professionals, patient advocacy and support groups, ongoing studies and clinical trials exploring new therapies, and rising healthcare expenditure. The market is expected to continue growing robustly, reaching $2.84 billion in 2028 at a CAGR of 8.4%, driven by an increase in diagnosed CSU cases, a growing patient pool, development of healthcare infrastructure, a favorable regulatory environment, patient-centric care models, and economic growth in emerging markets. Major trends include technological innovations, advancements in biological therapies, personalized medicine, the rise of telemedicine and digital health, advanced diagnostic tools, AI and machine learning, and a surge in drug approvals and launches.
Global Chronic Spontaneous Urticaria Market Key Driver
The growth of the chronic spontaneous urticaria market is expected to be fueled by increasing alcohol consumption. Various factors such as social norms, stress, advertising, affordability, and availability contribute to rising alcohol consumption, which can exacerbate chronic spontaneous urticaria symptoms like hives and swelling. For instance, in February 2024, rehabs.UK reported that 55% of men and 41% of women consumed alcohol weekly, with 8% of men and 5% of women drinking almost daily. From 2021 to 2022, there were 342,795 hospital admissions solely attributable to alcohol, translating to 626 admissions per 100,000 people. Consequently, rising alcohol consumption is driving growth in the chronic spontaneous urticaria market.
Get A Free Sample Of The Chronic Spontaneous Urticaria Market ReportGlobal Chronic Spontaneous Urticaria Market Segments
The chronic spontaneous urticaria market covered in this report is segmented –
1) By Treatment: Medication, Phototherapy, Other Treatments
2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administration
3) By Diagnosis: Physical Examination, Blood Test, Allergy Test, Other Diagnosis
4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users
By Geography:The regions covered in the chronic spontaneous urticaria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the chronic spontaneous urticaria market in 2023.
Major Chronic Spontaneous Urticaria Industry Players
F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.
Purchase The Global Chronic Spontaneous Urticaria Market Report Directly And Get A Swift DeliveryChronic Spontaneous Urticaria Market Overview
Chronic spontaneous urticaria (CSU) is a skin condition characterized by the recurrent appearance of hives (raised, red, itchy welts) and angioedema (swelling) lasting for more than six weeks, without an identifiable external trigger. The exact cause of CSU is often unknown, but it may involve an autoimmune component where the body's immune system mistakenly attacks healthy skin cells. Treatment focuses on symptom management, primarily using antihistamines and, in more severe cases, other medications such as biologics.
Chronic Spontaneous Urticaria Global Market Report 2023 provides data on the global chronic spontaneous urticaria market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The chronic spontaneous urticaria market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.